NCT05115474
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have evidence of stage IV extracranial disease (outside of the brain) having progressed past first line therapy
Exclusions: Patients with prior diagnosis or treatment of brain metastases or leptomeningeal disease; Patients with neurologic symptoms
https://ClinicalTrials.gov/show/NCT05115474